Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Spasticity - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering.
The "Spasticity - Pipeline Insight, 2025" report delivers an in-depth analysis of the spasticity drug pipeline, providing comprehensive insights on over 10 companies and more than 12 pipeline drugs.
The report profiles both clinical and nonclinical stage products, covering a wide range of therapeutic assessments by product type, development stage, administration route, and molecule type. It also spotlights inactive pipeline products offering a complete view of this critical healthcare area.
Spasticity, a type of motor disorder marked by increased muscle tone, often results in challenges like mobility issues and muscle spasms. However, it can have functional benefits such as improved circulation. A multifaceted management approach, including physical therapy and pharmacologic interventions, typically guides treatment. Accurate early assessment is crucial to optimize patient outcomes and enhance quality of life. The report offers a detailed exploration of these aspects, helping to frame the current and future therapeutic landscape.
The report identifies emerging drugs like MTR-601 by Motric Bio, a promising antispastic therapy in Phase II, and Ipsen's IPN10200, a long-acting botulinum neurotoxin for upper limb spasticity, currently in Phase I/II. These innovations underscore the commitment of industry leaders to advancing Spasticity treatment and improving patient outcomes.
The Spasticity report provides a strategic look at unmet needs, pipeline product profiles, and therapeutic assessments. It answers key questions regarding the evolution of Spasticity drugs, ongoing clinical studies, industry collaborations, and novel technologies, ensuring stakeholders are equipped with the knowledge to make informed strategic decisions.
Key highlights of the report include:
- Insights into various drug candidates, classified across different clinical development phases such as Phase III, II, I, Preclinical, and Discovery stages. Detailed drug descriptions include mechanisms of action, clinical trials, approvals, and developmental activities like mergers, acquisitions, and collaborations.
- A comprehensive therapeutic assessment that categorizes emerging Spasticity drugs based on routes of administration-oral, intravenous, subcutaneous, parenteral, topical-and various molecule types, including recombinant fusion proteins, small molecules, monoclonal antibodies, and peptides.
- An emphasis on key industry players such as Motric Bio, Ipsen, Saol Therapeutics Inc., Elpida Therapeutics SPC, Celgene, and Tris Pharma, Inc. Notable products under development include MTR-601 and IPN10200, which aim to offer groundbreaking solutions to Spasticity management.
- Analysis of pipeline activities, collaboration ventures, licensing, and acquisition efforts to highlight ongoing efforts and industry trends within Spasticity therapeutics.
Key Topics Covered:
Executive Summary
Spasticity: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Spasticity - Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
MTR-601: Motric Bio
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I/II)
- Comparative Analysis
IPN10200: Ipsen
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Spasticity Key Companies
Spasticity Key Products
Spasticity - Unmet Needs
Spasticity - Market Drivers and Barriers
Spasticity - Future Perspectives and Conclusion
Spasticity Analyst Views
Spasticity Key Companies
- Motric Bio
- Ipsen
- Saol Therapeutics Inc
- Elpida Therapeutics SPC
- Celgene
- Tris Pharma, Inc.
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/rr4rbb
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
